Please assess the completion status of the following clinical trial:

Trial Title: Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers, 18-65 years of age~* Meets Diagnostic and Statistical Manual of Mental Disorders Fourth Addition (DSM-IV) criteria for current alcohol dependence~* Subjects will not be seeking treatment because the medication studies are not treatment trials~* Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session~* Negative Breath Alcohol Concentration (BAC) and a Clinical Institute Withdrawal Assessment-Alcohol (CIWA-A) score of \< 8 at screening and time of lab session to eliminate acute alcohol or withdrawal effects on dependent measures~* Subjects must be able to complete and understand questionnaires and study procedures in English and sign an informed consent~Exclusion Criteria:~* Significant medical disorders that will increase potential risk or interfere with study participation as determined by the Study Physician~* Female subjects with childbearing potential who are pregnant, nursing, or refuse to use double barrier (non-hormonal) methods of birth control for the duration of the study and one month thereafter~* Meets DSM-IV criteria for a major Axis I disorder including mood or anxiety disorders or substance dependence disorders other than alcohol or nicotine dependence~* History of allergy or hypersensitivity to the study drugs or the ingredients~* Treatment within the month prior to screening with 1.) an investigational drug or vaccine; 2.) drugs that may influence study outcomes, e.g., disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral), anticonvulsants, antidepressants.~* In need of or currently taking any psychoactive medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Korlym (mifepristone) (Type: ACTIVE_COMPARATOR): 600 mg daily taken orally for one week
- Sugar Pill (Type: PLACEBO_COMPARATOR): placebo pill daily taken orally for one week

Based on this trial design, predict the completion outcome and termination type (if applicable).